Olevaprubart vs Vedastotug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: OX40 · full Atopic Dermatitis pipeline
Olevaprubart
Developed by Inmagene Biopharmaceuticals
NCT05984784 · Phase 1/2 · terminated
The trial was stopped before its randomized, placebo-controlled design could be completed, and the results that were reported cover only one active-dose group with no placebo comparison, so no controlled treatment effect can be assessed from the available data.
Next expected readout: December 2027 · NCT07037901 (registry estimate)
Reported efficacy
Evaluation of Adverse Events in Participants (Adverse events were collected from baseline through the end of the study, a period of up to 24 weeks.): Evaluation of Adverse Events in Participants (Adverse events were collected from baseline through the end of the study, a period of up to 24 weeks.): Cohort 1 IMG-007 Dose 1 — Participants with at least 1 TEAE: 9 participants; SAE: 0 participants; Investigational product-related TEAE: 0 participants; TEAE that was an infusion-related reaction: 0 participants; TEAE leading to 4-week dosing period discontinuation: 0 participants; TEAE with outcome of death: 0 participants (not_applicable)
Result source: NCT05984784
Vedastotug
Developed by Bio-Thera Solutions
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06094179 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Olevaprubart | Vedastotug |
|---|---|---|
| EASI-75 | —Not reported | —Not reported |
| IGA 0/1 with 2-point improvement | —Not reported | —Not reported |
| EASI-90 | —Not reported | —Not reported |
| EASI, % change | —Not reported | —Not reported |
EASI-75
- Olevaprubart
- —Not reported
- Vedastotug
- —Not reported
IGA 0/1 with 2-point improvement
- Olevaprubart
- —Not reported
- Vedastotug
- —Not reported
EASI-90
- Olevaprubart
- —Not reported
- Vedastotug
- —Not reported
EASI, % change
- Olevaprubart
- —Not reported
- Vedastotug
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Vedastotug: no structured comparison results are available for Atopic Dermatitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Olevaprubart: 3 of 4 rows · Vedastotug: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olevaprubart |
|---|---|
| Dropout rate | 38.5% NCT05984784 · Phase 1/2 · monotherapy · Atopic Dermatitis · phase 1/2 |
| Discontinued due to AEs | — NCT05984784 · Phase 1/2 · monotherapy · Atopic Dermatitis · phase 1/2 |
| Serious AEs | 0% NCT05984784 · Phase 1/2 · monotherapy · Atopic Dermatitis · phase 1/2 |
| Most frequent reported AEs | dermatitis atopic 30.8% hypertension 15.4% urticaria 15.4% NCT05984784 · Phase 1/2 · monotherapy · Atopic Dermatitis · phase 1/2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olevaprubart
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olevaprubart's landscape · Vedastotug's landscape